release tablet contains 40 mg of Pantoprazole ,Each prolonged-
Sponsors
The Government Pharmaceutical Organization
Conditions
Healthy male and female subjects.
Unknown Phase
An Open Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Oral Dose, Crossover Bioequivalence Study of Pantoprazole GPO (40 mg) (Pantoprazole 40 mg Delayed-Release Tablets) of The Government Pharmaceutical Organization, Thailand with CONTROLOC (Pantoprazole 40 mg Gastro-Resistant Tablets) of Takeda GmbH, Germany, in Normal, Healthy, Adults Human Subjects under Fasting Conditions
Active, not recruitingTCTR20190826001
Start: 2019-10-10Target: 42Updated: 2026-08-03
An Open Label, Randomized, Two-Treatment, Four-Period, Two-Sequence, Single Oral Dose, Crossover, Fully Replicate Bioequivalence Study of Pantoprazole GPO (40 mg) (Pantoprazole 40 mg Delayed-Release Tablets) of The Government Pharmaceutical Organization, Thailand with CONTROLOC (Pantoprazole 40 mg Gastro-resistant Tablets) of Takeda GmbH, Germany, in Normal, Healthy, Adults Human Subjects under Fed Conditions
Active, not recruitingTCTR20191114002
Start: 2020-01-22Target: 36Updated: 2026-08-03